Buprenorphine for Pain and for Addiction
description
Transcript of Buprenorphine for Pain and for Addiction
![Page 1: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/1.jpg)
Buprenorphine for Pain and for Addiction
David A. Moltz, MD
MAPP Clinical Conference
April 30, 2010
![Page 2: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/2.jpg)
I. Addiction and Dependence
![Page 3: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/3.jpg)
DSM IVSubstance Dependence
A maladaptive pattern of substance use, with 3 or more of:• Tolerance• Withdrawal• Using larger amounts or for a longer time than intended• Persistent desire or lack of control• A great deal of time spent obtaining, using, recovering
from• Important activities given up• Continued use in spite of negative consequences
![Page 4: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/4.jpg)
Addiction
A chronic but treatable brain disease characterized by loss of control compulsive use use despite known harm relapse
![Page 5: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/5.jpg)
• Addiction may occur with or without the presence of physical dependence.
• Physical dependence results from the body’s adaptation to a drug or medication and is defined by the presence of
– Tolerance and/or
– Withdrawal
Dependence vs Addiction
![Page 6: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/6.jpg)
• According to the 2002 National Survey on Drug Use and Health : An estimated 4.4 million persons were current users of pain relievers for nonmedical purposes.
• New non-medical pain reliever use more than quadrupled from 1990 (628,000 new users) to 2000 (2.7 million new users).
Opioid Use in a Household Survey Population
SOURCE: SAMHSA, 2002.
![Page 7: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/7.jpg)
Neural circuitry of reward
Present in all animals Produces pleasure for
behaviors needed for survival: Eating Drinking Sex Nurturing
![Page 8: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/8.jpg)
Neural circuitry of reward
Altruism activates the same circuitry
Meeks TW, Jeste DV. The neurobiology of wisdom. Arch Gen Psychiatry 2009;66(4):355-365
![Page 9: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/9.jpg)
II. Buprenorphine
![Page 10: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/10.jpg)
Definition of Terms
• Agonist
• Antagonist
• Affinity
• Intrinsic Activity
• Dissociation
![Page 11: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/11.jpg)
Buprenorphine
Novel opioid with both agonist and antagonist properties
Partial agonist at mu opioid receptor High affinity Low intrinsic activity Slow dissociation Antagonist at kappa receptor
![Page 12: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/12.jpg)
Buprenorphine
• High affinity for mu receptors ability to compete with full mu agonists (such as heroin) and to block their effects.
• Low intrinsic activity feeling of well-being without full opioid effects
• Very slow dissociation rate prolonged therapeutic effects.
• Ceiling effect
![Page 13: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/13.jpg)
1 0 0
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
0
- 1 0 - 9 - 8 - 7 - 6 - 5 - 4
%E ffi c a c y
L o g D o s e o f O p io id
F u ll A g o n is t( M e th a d o n e )
P a r t ia l A g o n is t( B u p re n o r p h i n e
A n t a g o n is t( N a lo x o n e )
O p ia t e P o t e n c y o f M e t h a d o n e , L A A M , a n d B u p r e n o r p h in eS li d e c o u rt es y o f L a u ra M c N ic h o la s , M D , P h D , U n iv o f P e n n .
![Page 14: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/14.jpg)
Advantages of a Partial Agonist
• Lower abuse potential
• Lower level of physical dependence
• Relative safety if ingested in overdose quantities
• Weak opioid effects compared with methadone.
![Page 15: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/15.jpg)
Blockade Effect
• Buprenorphine has tight binding to and slow dissociation from opioid receptors. It produces a blockade effect at the mu-opioid receptor so that subsequently administered opioids do not produce their full euphoric effect.
• It appears to produce less physical dependence than a full opioid agonist (such as methadone), and it may be easier to discontinue at the end of medication treatment.
![Page 16: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/16.jpg)
Kosten T and O'Connor P. N Engl J Med 2003;348:1786-1795
Severity of Opioid-Withdrawal Symptoms after Abrupt Discontinuation of Equivalent Doses of Heroin, Buprenorphine, and Methadone
![Page 17: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/17.jpg)
III. Buprenorphine for Addiction
![Page 18: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/18.jpg)
Drug Addiction Treatment Act of 2000 (DATA 2000)
• Expands treatment options to include both the general health care system and opioid treatment programs.– Expands number of available treatment slots– Allows opioid treatment in office settings– Sets physician qualifications for prescribing
the medication
![Page 19: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/19.jpg)
Blocks craving Blocks opiate withdrawal Does not produce a ‘high’ Blocks the effects of other opioids Milder withdrawal than methadone Stabilization of brain function Anti-depressant / anti-anxiety effect
Beneficial Effects
![Page 20: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/20.jpg)
Significant enhancement in treatment retention and in the quality of participation
Mainstreaming of opioid dependence treatment with office-based practice
Greater safetyLower diversion risk
Beneficial Effects
![Page 21: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/21.jpg)
Research Outcomes
• Buprenorphine is as effective as moderate doses of methadone.
• Partial agonist effects make it mildly reinforcing, encouraging medication compliance.
• After a year of buprenorphine + counseling, 75% of patients were retained in treatment compared to 0% in a placebo + counseling condition.
![Page 22: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/22.jpg)
B u p re n o rp h in e , M e t h a d o n e , L A A M :U r in e T e s t i n g fo r O p io id s
Mea
n %
Neg
ativ
e
S t u d y W e e k
A l l S u b j e c t s
L o M e t h a d o n e
B u p r e n o r p h i n e
H i M e t h a d o n e
L A A M
1 3 5 7 9 1 1 1 3 1 5 1 70
2 0
4 0
6 0
8 0
1 0 0
1 9 %
4 0 %
3 9 %
4 9 %
A d a p te d f r o m J o h n s o n , e t a l . , 2 0 0 0
![Page 23: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/23.jpg)
Cognitive Effects
• Available evidence in patients maintained on buprenorphine indicates no clinically significant disruption in cognitive and psychomotor performance.
• “Long-term use…does not impair driving ability.”
Dagtekin O, et al. Assessing cognitive & psychomotor Performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth Analg 2007;105:1442-8
![Page 24: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/24.jpg)
Suboxone
• Buprenorphine + naloxone
• Partial agonist + pure antagonist
• Naloxone is only active intravenously
• Will precipitate withdrawal in opioid-dependent individuals
• Combination decreases diversion risk
![Page 25: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/25.jpg)
Addiction is not a disease of the synapses alone
--Mark Publicker
![Page 26: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/26.jpg)
IV. Buprenorphine and Pain
![Page 27: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/27.jpg)
Pain Patients vs Addicted Persons
![Page 28: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/28.jpg)
Risk Factors
• Psychosocial
• Genetic
• Drug-related
![Page 29: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/29.jpg)
Pseudo-addiction
• “Drug-seeking behavior”
• Consequence of inadequate treatment of pain
• May be indistinguishable from addictive behavior
![Page 30: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/30.jpg)
Effectiveness in Pain
• 30-40 times more potent than morphine
• Ceiling effect high safety profile
• Transdermal used extensively in Europe
• “…transdermal buprenorphine provides effective, sustained and dose-dependent analgesia, irrespective of age.”
Pergolizzi J et al. Opioids & the management of chronic severe pain in the elderly: Consensus statement of an international expert panel. Pain Practice 2008;8(4):287-313
![Page 31: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/31.jpg)
Buprenorphine vs Morphine
• Chronic cancer pain
• More effective than morphine for physical pain, mental health and quality of life.
Pace, MC, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Frontiers in Bioscience 2007;(12):1291-1299
![Page 32: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/32.jpg)
Buprenorphine vs Methadone
• Post-partum, maintained on buprenorphine or methadone, with opioids or ibuprofen as needed
• Buprenorphine group decreased ibuprofen use over 5 days
• Methadone group increased ibuprofen use
Jones HE, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug and Alcohol Abuse, 2009; 35:151-56
![Page 33: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/33.jpg)
Managing Pain During Buprenorphine Maintenance
• Supplement with NSAIDS
• Temporarily replace buprenorphine with opiates
• Override buprenorphine with opiates
• Divide +/or increase buprenorphine dose
Heit HA, Gourlay DL. Buprenorphine: New tricks with an old molecule for pain management.
Clin J Pain 2008; 24(2):93-97
![Page 34: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/34.jpg)
Hyperalgesia
![Page 35: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/35.jpg)
Hyperalgesia
• A decrease in the threshold to elicit pain
• A state of nociceptive sensitization
• Hyperesthesia
![Page 36: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/36.jpg)
Allodynia
The generation of pain in response to low-intensity stimuli or stimuli that are not normally painful.
![Page 37: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/37.jpg)
Mechanisms of Hyperalgesia
• NMDA (glutaminergic)
• Dynorphin (kappa receptor agonist)
• Peripheral, spinal and central sensitization
• “More complexity than clarity”
![Page 38: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/38.jpg)
Opioid-Induced Hyperalgesia
• May be activation of hyperalgesic systems to counteract the analgesic effects of the opioids
• Ex: Morphine activates NMDA receptors and spinal dynorphin
• In withdrawal, the hyperalgesic system is unopposed
![Page 39: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/39.jpg)
Hyperalgesia and Tolerance
• May share mechanisms (eg,NMDA), but they are clinically different
• Hyperalgesia is increased sensitivity to pain
• Tolerance is decreased sensitivity to opioids
Chang G, et al. Opioid tolerance & hyperalgesia. Med Clin N Am 2007;91;199-211
![Page 40: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/40.jpg)
OIH and Tolerance
• Difficult to differentiate clinically
• OIH diffuse, generalized pain, often different from pre-existing pain
• Stopping the opioid can differentiate– Tolerance more pain– OIH less pain
![Page 41: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/41.jpg)
Treating OIH
• Minimize opioid dose using adjuvant therapies
• Opioid rotation
• Methadone (NMDA antagonist)
• Buprenorphine
![Page 42: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/42.jpg)
Pain reduction after detoxification
• 23 patients not getting benefit from high-dose opioids
• No addictive behaviors
• 21 showed marked decrease in pain after detoxification
• After weaning, 63% decrease in pain with buprenorphine vs. 47% without
Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Management 2006;2(5):277-282
![Page 43: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/43.jpg)
Neuropathic pain
• Buprenorphine relieves allodynia from neuropathic pain
• Blocks hyperalgesia due to central hypersensitization
• Kappa antagonist (dynorphin)• “Buprenorphine has been shown to have a
pronounced antihyperalgesic effect.”
Induru RR, Davis MP. Buprenorphine for neuropathic pain – Targeting hyperalgesia. Am J Hospice & Palliative Med 2009:26 (6);470-3
Likar R. Transdermal buprenorphine in the management of persistent pain – Safety aspects. Therapeutics & Clinical Risk Management 2006:2(1):115-125
![Page 44: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/44.jpg)
Buprenorphine and OIH
• “Resolution of OIH usually follows quickly during the maintenance phase with buprenorphine.”
• “Buprenorphine may be unique in its ability to treat chronic pain and possibly OIH”
• Silverman SM. Opioid induced hyperalgesia: Clinical implications for the pain practitioner.
![Page 45: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/45.jpg)
Prescription Opioid Addiction Treatment Study (POATS)
• Opioid dependence
• 42% with co-existent chronic pain
• Overall, 49% substantially improved after 3 mo of buprenorphine
• Of those with chronic pain, 53% substantially improved, and “many had significant improvement in their pain.”
Weiss R. NIDA Blending Conference 4/22/10. www.NIDA.NIH.Gov
![Page 46: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/46.jpg)
Coexistent Addiction and Pain
• Buprenorphine is ideal
• Treats addiction
• Treats pain
• Relieves hyperalgesia
![Page 47: Buprenorphine for Pain and for Addiction](https://reader036.fdocuments.in/reader036/viewer/2022062305/5681572e550346895dc4c97a/html5/thumbnails/47.jpg)
Resources
• Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. SAMHSA/CSAT Treatment Improvement Protocols. TIP 40.
• http://buprenorphine.samhsa.gov• http://www2.aaap.org/buprenorphine
(For DATA training)